Trial · NCT03669588
Results by group12
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 12 of 12
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of MG-ADL Responders During Cycle 1 (C1); Analyzed in the AChR-Ab Seropositive Population | ARGX-113 | 67.7 | percentage of patients | ||
| Percentage of MG-ADL Responders During Cycle 1 (C1); Analyzed in the AChR-Ab Seropositive Population | Placebo | 29.7 | percentage of patients | ||
| Percentage of Quantitative Myasthenia Gravis (QMG) Responders During C1; Analyzed in the AChR-Ab Seropositive Population | ARGX-113 | 63.1 | percentage of patients | ||
| Percentage of Quantitative Myasthenia Gravis (QMG) Responders During C1; Analyzed in the AChR-Ab Seropositive Population | Placebo | 14.1 | percentage of patients | ||
| Percentage of MG-ADL Responders During C1; Analyzed in the Overall Population | ARGX-113 | 67.9 | percentage of patients | ||
| Percentage of MG-ADL Responders During C1; Analyzed in the Overall Population | Placebo | 37.3 | percentage of patients | ||
| Percentage of Time That Patients Had a Clinically Meaningful Improvement (CMI) in MG-ADL Total Score up to and Including Day 126; Analyzed in the AChR-Ab Seropositive Population | ARGX-113 | 48.714 | Standard Error 6.163 | percentage of time | |
| Percentage of Time That Patients Had a Clinically Meaningful Improvement (CMI) in MG-ADL Total Score up to and Including Day 126; Analyzed in the AChR-Ab Seropositive Population | Placebo | 26.649 | Standard Error 6.316 | percentage of time | |
| Time From Week 4 to Qualify for Retreatment; Analyzed in the AChR-Ab Seropositive Population | ARGX-113 | 35.0 | 95% Confidence Interval 29.0 to 43.0 | days | |
| Time From Week 4 to Qualify for Retreatment; Analyzed in the AChR-Ab Seropositive Population | Placebo | 8.0 | 95% Confidence Interval 1.0 to 30.0 | days | |
| Percentage of Early MG-ADL Responders During C1; Analyzed in the AChR-Ab Seropositive Population | ARGX-113 | 56.9 | percentage of patients | ||
| Percentage of Early MG-ADL Responders During C1; Analyzed in the AChR-Ab Seropositive Population | Placebo | 25.0 | percentage of patients |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03669588/results